Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 289

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 289
---
ee Oxygen and Lumee Glucose. Market segments for Lumee Glucose included Type 1 and Type 2 diabetics, Type 2 diabetics not on insulin, prediabetic, and the emerging health and wellness segment. The market segments used for Lumee Oxygen were the critical limb ischemia (CLI) and peripheral arterial disease (PAD) segment. The table below shows the total addressable patient population across the market segments discussed above for each of Lumee Glucose and Lumee Oxygen in each of the United States and the Europe Union. The numbers below are presented in millions.

| Product Line  |     | Region |     |  2026 |     |  2027 |     |  2028 |     |  2029 |     |  2030 |
| Lumee Glucose |     | US     |     | 35.85 |     | 37.53 |     | 39.34 |     | 41.31 |     | 43.49 |
| Lumee Glucose |     | EUR    |     | 38.31 |     | 40.08 |     | 41.99 |     | 44.08 |     | 46.37 |
| Lumee Oxygen  |     | US     |     | 31.94 |     | 32.26 |     | 32.58 |     | 32.91 |     | 33.24 |
| Lumee Oxygen  |     | EUR    |     | 40.70 |     | 41.63 |     | 42.57 |     | 43.73 |     | 44.71 |

Management then applied estimates of Lumee Oxygen and Lumee Glucose penetration rates in each of the market segments. The average estimated penetration rate for Lumee Glucose across all market segments in Europe ranged from .03% in 2026 to an average .88% in 2030. Penetration rates for Lumee Glucose across all market segments in the US ranged from an average of .0001% in 2026 to an average .87% in 2030. The penetration rates estimated for Lumee Oxygen in the European market for PAD and CLI averaged .23% in 2026 to an average 1.73% in 2030. The average penetration rates in the US for both the PAD and CLI markets averaged .25% in 2026 rising to an average of 2